ACE inhibitors (ACEi) and angiotensin receptor blockers (ARBs) are some of the highest-yield “renal physiology in drug form” topics on Step 1. They’re used everywhere (HTN, CHF, diabetic nephropathy), but the test writers love asking when they help the kidney vs when they acutely drop GFR and cause a creatinine bump. If you can visualize what’s happening at the efferent arteriole and the glomerulus, most questions become automatic.
Big Picture: What ACEi/ARBs Do in the Kidney
Definitions (Step-style)
- ACE inhibitors (ACEi): block ACE → ↓ angiotensin II, ↑ bradykinin
- Examples: -pril (lisinopril, enalapril, captopril)
- ARBs: block angiotensin II receptor (AT1) → ↓ angiotensin II signaling (no bradykinin increase)
- Examples: -sartan (losartan, valsartan)
The key renal hemodynamic move
Angiotensin II preferentially constricts the efferent arteriole to maintain glomerular capillary pressure when renal perfusion is low.
So:
- ACEi/ARB → efferent dilation → ↓ intraglomerular pressure → ↓ GFR (acutely)
- But also:
- ACEi/ARB → ↓ intraglomerular hypertension → ↓ proteinuria and slows CKD progression (chronically)
If you remember only one sentence for Step 1:
ACEi/ARBs dilate the efferent arteriole, causing an acute fall in GFR but long-term renal protection in proteinuric disease.
Pathophysiology Deep Dive (Why they’re protective in CKD)
In proteinuric CKD (esp. diabetes)
Chronic hyperfiltration and high intraglomerular pressure injure podocytes and the GBM → albuminuria and progressive scarring.
ACEi/ARBs help by:
- Lowering intraglomerular pressure (efferent dilation)
- Reducing protein filtration → less tubular inflammation and fibrosis
- Reducing aldosterone → less Na⁺ retention (BP control helps kidneys too)
High-yield association: They reduce microalbuminuria and slow progression of diabetic nephropathy.
Clinical Presentation: What Step Questions Look Like
1) “Creatinine bump after starting lisinopril”
- Patient with CKD/HTN (or diabetics) starts ACEi → serum creatinine rises within days
- This can be expected to a point:
- A rise of up to ~30% can be acceptable clinically (Step more often frames it as “mild rise expected” vs “dangerous scenario below”).
2) “Hyperkalemia after ACEi/ARB”
- ↓ aldosterone → ↓ K⁺ secretion in principal cells → hyperkalemia
- ECG changes and arrhythmia risk show up in more Step 2–style stems.
3) “Dry cough/angioedema”
- ACEi (not ARBs) → ↑ bradykinin → dry cough, angioedema
- Step move: switch to an ARB if cough occurs.
4) Pregnancy contraindication (classic)
- ACEi/ARBs are teratogenic → fetal renal damage (oligohydramnios, renal failure; “ACEi causes fetal kidney problems” is the testable takeaway).
Diagnosis: How to Recognize When ACEi/ARB Is Dangerous
The must-know contraindication setup: Renal artery stenosis
Angiotensin II is compensating for reduced renal perfusion by constricting efferent arterioles to preserve GFR. Block it and GFR can crash.
Unilateral renal artery stenosis
- The affected kidney may lose GFR, but the other kidney can maintain overall renal function.
- Creatinine may rise mildly.
Bilateral renal artery stenosis (or stenosis in a solitary kidney)
- ACEi/ARB can cause a big fall in GFR → marked creatinine rise/AKI.
Classic Step clue:
- Older patient with diffuse atherosclerosis OR younger woman with fibromuscular dysplasia
- Abdominal bruit, resistant HTN
- Then ACEi initiation → big creatinine rise
Table: ACEi/ARB effect by scenario (high yield)
| Scenario | What’s maintaining GFR? | ACEi/ARB effect on efferent arteriole | Net effect on GFR | Step takeaway |
|---|---|---|---|---|
| Normal physiology | baseline tone | dilate | slight ↓ | usually tolerated |
| Diabetic nephropathy (proteinuria) | hyperfiltration | dilate | slight ↓ acutely | renal protective long-term |
| CHF/low effective arterial blood volume | Ang II compensation | dilate | ↓ | can worsen renal function early |
| Bilateral renal artery stenosis | Ang II critical | dilate | large ↓ | contraindicated → AKI |
Treatment: When and Why You Use Them in Renal Disease
Indications (renal-focused)
- Diabetic nephropathy (especially with albuminuria)
- Proteinuric CKD (many etiologies): reduces proteinuria, slows progression
- Hypertension with CKD (common first-line depending on potassium/creatinine status)
Monitoring (Step-relevant labs)
- Serum creatinine (for AKI signal)
- Serum potassium (for hyperkalemia)
Managing adverse effects (test logic)
- Cough/angioedema: due to bradykinin (ACEi) → switch to ARB
- Hyperkalemia: consider stopping K⁺ supplements/K⁺-sparing diuretics; adjust therapy
- AKI in renal artery stenosis: stop ACEi/ARB and address stenosis/volume status
HY Associations & “Buzz Phrases” You’ll See
ACEi/ARB: the “efferent arteriole” drugs
- NSAIDs constrict afferent (↓ prostaglandins)
- ACEi/ARB dilate efferent (↓ angiotensin II)
- Diuretics can reduce plasma volume (↓ perfusion)
- The “triple whammy” concept (more Step 2, but great physiology integration):
NSAID + diuretic + ACEi/ARB → prerenal AKI risk
Aldosterone linkage → potassium and acid-base
- ↓ aldosterone → hyperkalemia
- Can contribute to a type 4 RTA–like picture (hypoaldosteronism physiology): hyperkalemia with mild metabolic acidosis (often more Step 2).
Pregnancy
- Contraindicated: fetal renal malformations/oligohydramnios (high yield)
Rapid-Fire Step 1 “If-Then” Rules
- If diabetic patient has microalbuminuria then ACEi/ARB helps reduce proteinuria and slows progression.
- If ACEi started and creatinine rises a little then that can be expected from efferent dilation.
- If ACEi started and creatinine jumps a lot then think bilateral renal artery stenosis (or solitary kidney stenosis), severe volume depletion, or other causes of low renal perfusion.
- If dry cough/angioedema then it’s bradykinin → ACEi side effect → use ARB instead.
- If hyperkalemia then suspect low aldosterone from ACEi/ARB (especially with CKD).
First Aid Cross-References (What to Review Alongside)
These are the First Aid concepts that most directly pair with ACEi/ARB renal questions:
- Renal Physiology: GFR & arteriolar tone
- Afferent vs efferent arterioles and how they change GFR and RPF
- Pharmacology: Antihypertensives
- ACEi adverse effects: cough, angioedema, hyperkalemia, teratogenicity
- ARBs: similar without cough (no bradykinin increase)
- Renal Pathology: Diabetic nephropathy
- Hyperfiltration → microalbuminuria → Kimmelstiel-Wilson nodules (path)
- ACEi/ARB: reduce proteinuria
(Page numbers vary by edition, but these topics are consistently clustered in the Renal + CV pharm sections.)
Mini Question Bank (Quick Self-Check)
Vignette 1
A 68-year-old man with long-standing HTN and abdominal bruit starts lisinopril. Two weeks later, creatinine rises from 1.1 to 2.3 mg/dL.
Most likely mechanism?
- Efferent arteriole dilation removing angiotensin II–mediated support of GFR in renal artery stenosis (likely bilateral/solitary kidney).
Vignette 2
A diabetic patient with new microalbuminuria is started on losartan.
Why this helps?
- Decreases intraglomerular pressure → decreases proteinuria → slows CKD progression.
Vignette 3
Patient on enalapril develops swelling of lips and tongue.
Next step?
- Stop ACEi (bradykinin-mediated angioedema); avoid re-challenge; often switch to ARB with caution in real practice (Step typically: “ARB instead of ACEi for cough”).
Take-Home Diagram (Put This in Your Brain)
- Ang II: constrict efferent → maintain GFR in low perfusion
- ACEi/ARB: dilate efferent → ↓ GFR acutely; ↓ proteinuria chronically
- Danger zone: bilateral renal artery stenosis, severe volume depletion → AKI
- Common labs: ↑ K⁺, ↑ creatinine (mild expected; large is bad)